Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies.

Stem cells translational medicine - 1 Aug 2016

Barazzetti Gaia, Hurst Samia A, Mauron Alexandre

Abstract excerpt

UNLABELLED: : As research on human embryonic stem cell (hESC)-based therapies is moving from the laboratory to the clinic, there is an urgent need to assess when it can be ethically justified to make the step from preclinical studies to the first protocols involving human subjects. We examined existing regulatory frameworks stating preclinical requirements relevant to the move to first-in-human (FIH) trials and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benchmarking
Share to Cell Lineage
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Embryonic Stem Cells

Share to Models, Animal

Share to Research Design

Share to Stem Cell Transplantation

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 27334488
DOI: 10.5966/sctm.2015-0222
PMCID: PMC4954447

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies.PMID 27334488Read ↗

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapySemantic proximity Read ↗

A few ethical issues in translational research for gene and cell therapySemantic proximity Read ↗

Developing Standards to Support the Clinical Translation of Stem CellsSemantic proximity Read ↗

Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s diseaseSemantic proximity Read ↗

Lessons learnt, and still to learn, in first in human stem cell trialsSemantic proximity Read ↗

Advancements in Human Embryonic Stem Cell Research: Clinical Applications and Ethical IssuesSemantic proximity Read ↗

ISSCR’s Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventionsSemantic proximity Read ↗

Defining Biomarkers in Stem Cell‐Derived Tissue Constructs for Drug and Disease ScreeningSemantic proximity Read ↗

Good Manufacturing Practice–compliant human induced pluripotent stem cells: from bench to putative clinical productsSemantic proximity Read ↗

Human embryonic stem cell technologies and drug discoverySemantic proximity Read ↗

Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem CellsSemantic proximity Read ↗

Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.